2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3660 Phase 1 study of TQB3107 in patients with relapsed/refractory (R/R) lymphomas

Zhiming Li, MD, Zheng Song, PhD2, Peng SUN, PhD3, Panpan LIU4, Yu Wang5, Hang Yang6, Huilai Zhang, PhD7
1 Sun Yat-Sen University Cancer Center, Guangzhou, China
2 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
3 Sun Yat-Sen University Cancer Center, Guangzhou, China
4 Sun Yat-Sen University Cancer Center, Guangzhou, China
5 Sun Yat-Sen University Cancer Center, Guangzhou, China
6 Sun Yat-Sen University Cancer Center, Guangzhou, China
7 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Background

Despite significant advances in targeted therapies and immunotherapies, patients (pts) with R/R malignant hematologic tumors who face a dismal prognosis with extremely limited salvage options. Novel approaches with distinct mechanisms of action are urgently needed to overcome drug resistance and improve clinical outcomes. TQB3107 is a novel oral second-generation XPO1 inhibitor that can improve tolerability by reducing blood-brain barrier penetration, thereby decreasing gastrointestinal toxicities such as nausea and weight loss. Preclinical studies indicated its anti-tumor activity across multiple malignancy types. This phase I study (NCT06413953) aimed to evaluate the safety, tolerability, and pharmacokinetic profile of TQB3107 in patients with malignant hematologic tumors.

Methods

This was an open-label, single-arm, phase I dose-escalation and dose-expansion study. Eligible patients aged 18–75 years who had no standard treatment options exist or who have progressed on or are intolerant to prior therapies are enrolled. TQB3107 was administered orally in a 28-day cycle under two sequential dosing regimens: Regimen 1 (5 days on / 2 days off weekly) with dose escalation from 2 mg to 20 mg, followed by Regimen 2 (every other day on days 1, 3, and 5 weekly) at a fixed dose of 20 mg until disease progression, intolerability or withdrawal of consent. Primary endpoints include dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and the recommended phase II dose (RP2D). Efficacy was assessed by Lugano criteria (2014) for patients with lymphoma.

Results

As of Feb 28, 2026, 32 pts were enrolled and received at least one dose, including 14 pts (43.8%) with diffuse large B-cell lymphoma (DLBCL), 4 (12.5%) peripheral T-cell lymphoma (PTCL), 4 (12.5%) Hodgkin lymphoma (HL), 3 (9.4%) follicular lymphoma (FL). The median age was 52.5 years (range 28-75). Sixteen (50%) pts had received at least 3 lines of prior treatments, including 4 pts with prior CD3 engager-based regimens (e.g., glofitamab + R-Gemox) and 1 pt with prior CAR-T therapy.

The most common treatment-emergent adverse events (TEAEs) were hematological toxicities. The most common (>10%) hematological TEAEs were neutropenia (84.4%), anemia (65.6%), thrombocytopenia (59.4%) and lymphocyte count decrease (31.3%). Grade≥3 hematological TEAEs included neutropenia (46.9%), thrombocytopenia (12.5%), lymphocyte count decrease (31.3%), anemia (3.1%) and hemophagocytic lymphohistiocytosis (3.1%). The most common (>20%) non-hematological TEAEs were diarrhea (37.5%), asthenia (37.5%), nausea (28.1%), ALT increased (25.0%), decreased appetite (25.0%), hypertriglyceridemia (25.0%), AST increased (21.9%), hyponatremia (21.9%), proteinuria (21.9%). Grade≥3 non-hematological TEAEs (≥5%) were asthenia (9.4%), decreased appetite (6.3%). Dose escalation was completed with two DLTs observed: one case of febrile neutropenia at the 12 mg dose level, and one case of bacteremia at 20 mg in Regimen 1, and the MTD was not reached.

In 31 efficacy-evaluable pts, four pts (12.9%) achieved complete response (CR). ORR was 29.0% (9/31) among all pts. Responses were observed across doses from 6 mg upward. Among 4 pts with prior CD3-engager exposure, 2 pts with DLBCL achieved CR. The longest durations of response were 10.4 months and 8.6 months in the 12 mg and 20 mg (Regimen 1) dose groups, respectively, with both patients continuing treatment at data cutoff.

Conclusions

TQB3107 showed a manageable safety profile with substantially low gastrointestinal toxicity in patients with R/R lymphomas. Encouraging antitumor activity was observed, including durable CRs in DLBCL patients with prior CD3-engager therapy, supporting further clinical development. Dose escalation and expansion are ongoing to determine the RP2D and further evaluate the anti-tumor activity of TQB3107.

Zhiming Li, MD: No relevant conflicts of interest to declare.